Literature summary for 2.7.10.2 extracted from

Traxler, P.; Bold, G.; Buchdunger, E.; Caravatti, G.; Furet, P.; Manley, P.; O'Reilly, T.; Wood, J.; Zimmermann, J.
Tyrosine kinase inhibitors: from rational design to clinical trials (2001), Med. Res. Rev., 21, 499-512.

Organism

Organism	UniProt	Comment	Textmining

Synonyms	Comment	Organism
Abl tyrosine kinase	present in 95% of patients with chronic myelogenous leukemia, CML	eukaryota

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)